# **IPO Report**

16 April 2021

### **IPO Expected Timetable#**

Stock Code	Stock Name	Application lists close	Allotment Date	Listing Date
06622	ZHAOKE OPHTH-B	2021/04/21	2021/04/28	2021/04/29

<sup>#</sup>IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit <a href="www.cfsg.com.hk">www.cfsg.com.hk</a> or contact our account executives or customer service officers

### **Subscription Details via CASH Securities**

Offer Period	2021/04/16-2021/04/21			
Closing Time for Margin Application	2021/04/20 2:00pm			
Subscription Fee	HKD 100			
Days For Margin Financing	7 days			
Indicative Interest Rate	2.38% (0.25% deductible^)			
	^Eligible new and existing customers who use the electronic direct debit authorization (eDDA) transfer service before the termination of the IPO subscription can enjoy a 0.25% loan interest reduction.			
*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.				

## Zhaoke Ophthalmology Limited (6622.HK)

## **Share Offer Highlights**

Total Number of Offer Shares: 123,567,500 Shares (subject to the Over-allotment Option)

- Number of Public Offer Shares: 12,357,000 Shares (subject to adjustment)

- Number of Placing Shares: 111,210,500 Shares (including 6,178,000 Reserved Shares under the Preferential

Offering) (subject to adjustment and the Over-allotment Option)

Number of Shares per Lot: 500 Shares

Offer Price: HKD 15.38-16.80 per Share

2020 Historical P/E ratio:

Sponsor: Goldman Sachs, Jefferies

#### **Company Overview**

The Company is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs in China. Leveraging its deep domain expertise, it has built a comprehensive ophthalmic drug pipeline of 25 candidates that covers most major ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an advanced ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of near-term product launch. Its goal is to become a leader in China and the neighboring ASEAN marketplace.

For the year ended December 31, 2019 and 2020, the Company's net losses were RMB 122.08 mn, and RMB726.98 mn respectively.

#### Source

# IPO Prospectus

ir O r iospectus		
Contact Us		
Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building,683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen 2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai	(86-755) 2216 5888 (86-21) 3227 9888
	Room 3316B, Block A, China Shine Plaza, 9 West Lin He Road, Tian He District, Guangzhou	(020) 8981 7463
	Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan	(86-769) 2223 0026



#### **Declaration:**

The above information is provided and distributed by CASH Financial Services Group Limited ( "CASH" ). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.